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Abstract
Chronic R-N6-phenylisopropiladenosine (R-PIA) subcutaneous injection for 6 days significantly increased total glutamate receptor
number (180% of control) in rat brain synaptic plasma membranes (SPM), without affecting receptor affinity. A higher increase in
metabotropic glutamate (mGlu) receptor number (258% of control) was also detected, indicating that mGlu is the main type of glutamate
receptor affected by this treatment. On the other hand, the observed increase in basal and calcium- and Gpp(NH)p-stimulated phospholipase
C (PLC) activity after treatment was associated with a significant increase in PLC h1 isoform, detected in SPM by immunoblotting assays.
Moreover, an increase in PLC activity stimulation with trans-ACPD, in the absence and in the presence of Gpp(NH)p, was detected after R-
PIA treatment. These results show that mGlu receptors and its effector system, PLC activity, are up-regulated by chronic exposure to an
adenosine A1 receptor agonist and suggest the existence of a cross-talk mechanism between both signal transduction pathways in rat brain.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Glutamate is the main excitatory neurotransmitter in the
central nervous system which has been implicated in differ-
ent physiological and pathological processes [1,2]. The
different actions of glutamate are mediated through gluta-
mate receptors, which have been classified into ionotropic
and metabotropic. Metabotropic glutamate (mGlu) receptors
are coupled, through G-proteins, to different effector sys-
tems, including phospholipase C (PLC) activation and
adenylyl cyclase (AC) inhibition [3,4]. In the central nerv-
ous system, several modulators regulate glutamate release,
and activation of adenosine A1 receptors play an important
role [5,6]. Four receptor types mediate adenosine actions,
named A1, A2A, A2B and A3 receptors. A1 and A3 receptors
are coupled through a Gi/o protein to AC inhibition, while
A2A and A2B receptors are coupled to AC stimulation
through a Gs protein [7,8].
Receptor-mediated activation of a given signal trans-
duction pathway by an agonist, not only modulates its
own signal transduction pathway but may also modulate
cellular responses through other different signalling path-
ways [9,10]. Previous studies have shown cross-talk pro-
cesses between transduction pathways mediated through
different G-protein coupled receptors, mainly involving h-
adrenergic receptors [11–15]. Changes elicited by these
cross-talk processes can affect all the transduction system
components (e.g. receptors, G-proteins and enzymatic activ-
ities). Effects at the post-receptor level have been well
documented. Thus, sensitization of the AC system after
stimulation of PLC through transfected m5 muscarinic
receptors in murine L-cells has been reported [16]. On the
other hand, Gi-protein down-regulation has been described
as a mechanism of heterologous regulation in adipocytes
[17]. Finally, although less studied, changes in receptors
have also been detected. Thus, activation of h2-adrenergic
receptors leads to down-regulation of m1 mAChR in CHO
cells [13] and an increased level of a-adrenergic receptor
mRNA in DDT1 MF-2 cells [11].
We have previously described in vitro the existence of
cross-talk between h-adrenergic/AC and mGlu/PLC path-
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ways in C6 glioma cells [18] and other authors have
described an increase in h-adrenergic receptors after persis-
tent activation of adenosine A1 receptors in DDT1 MF-2
cells [12]. Although several reports have shown the exis-
tence of cross-interaction between mGlu and adenosine
receptors in vitro or ex vivo systems [19–23], including
formation of functionally interacting complexes [24], how-
ever, little is known about cross-talk between these receptors
after chronic in vivo activation of one of these signal
transduction pathways.
The aim of the present work was to determine the effect
of chronic R-PIA administration to rats on mGluR/PLC
transduction pathway. We report that adenosine A1 receptor
activation with R-PIA causes an up-regulation of both mGlu
receptors and PLC activity in rat brain, suggesting that a
cross-talk mechanism is operating between glutamate- and
adenosine-mediated transduction pathways.
2. Materials and methods
2.1. Animal treatment
Three-month-old male rats (180–200 g of body weight),
kept on a 12 h light/12 h dark cycle and with free access to
food and drinking water were treated by subcutaneous
injection with R-PIA (one dose of 187 Ag/day) during 6
days. Control rats were injected in parallel with vehicle. The
7th day rats were sacrificed by cervical dislocation and
synaptic plasma membranes (SPM) from theirs brains were
isolated. All experiments followed the European Commun-
ity regulations about animal experimentation.
2.2. Materials
Phosphatidyl [2-3H] inositol 4,5-bisphosphate (1 Ci/
mmol) was purchased from Amersham. L-[3H]glutamic acid
(54.7 Ci/mmol) was from List Biological Laboratories (New
England Nuclear). Non-hydrolyzable guanine nucleotides
were from Roche. Trans-ACPD was from Tocris (Essex,
UK). Nitrocellulose membrane and electrophoresis reagents
were from Biorad Laboratories. Monoclonal antibody to
PLC h1 isoform was from UBI (Lake Placid, NY, USA). R-
PIA was from Sigma. ECL Western blotting detection
system was from Amersham. All other reagents were ana-
lytical grade.
2.3. Synaptic plasma membranes isolation
Brains were homogenized (1:10 w/v) in TDE buffer (5
mM Tris–HCl buffer pH 7.4, containing 1 mM dithio-
threitol, 1 mM EGTA, 100 AM PMSF, 7.3 mU/ml baci-
tracin) and 10% sucrose (w/v) with a motor-driven Teflon
glass tissue grinder. SPM were isolated as described earlier
[25]. The homogenate was centrifuged at 800 g for 10
min. Pellet was dissolved in TDE buffer and centrifuged at
9000 g for 20 min. The washed pellet was resuspended
in TDE buffer pH 8 and incubated at 4 jC for 30 min. This
membrane preparation was adjusted to 34% (w/v) sucrose
in TDE buffer and placed at the bottom of nitrocellulose
tubes. A discontinuous sucrose gradient was formed and
centrifuged at 60,000 g for 110 min at 4 jC in a SW40
rotor (Beckman). The material layered at the interface
between the 34% and 28.8% sucrose was collected. This
fraction was diluted 3-fold with TDE buffer and centri-
fuged at 150,000 g for 60 min. The pellet was resus-
pended in TDE and frozen to  70 jC until assays were
performed.
2.4. L-[3H]glutamate binding assays to synaptic plasma
membranes
L-[3H]Glutamate binding assays to rat membranes were
performed as described previously [26]. Briefly, membranes
were treated with 0.04% Triton X-100 to facilitate the
removal of endogenous glutamate [27]. To determine mGluR
binding, 60–100 Ag of protein were incubated for 60 min at
25 jC in the presence of 100 AM a-amino-3-hydroxy-5-
methyl-isoxazole-4 propionic acid (AMPA), 100 AM kai-
nate, and 100 AM N-methyl-D-aspartic acid (NMDA), in
order to block ionotropic glutamate binding, and different L-
[3H]glutamate concentrations (40–1500 nM) with 10 mM
potassium phosphate pH 7.4, in the presence or in the
absence of unlabeled L-glutamate to obtain non-specific
binding. All assays were performed in the presence of 1
mM DL-threo-h-hydroxyaspartic acid (THBA), a L-glutamate
uptake inhibitor [28].
2.5. Phospholipase C activity determination
PLC activity in SPMswas assayed as described previously
[29], using [3H]PtdInsP2 as exogenous substrate. Assays
were carried out for 10 min at 37 jC incubating 7.5 pmol
[3H]PtdInsP2 with 10–15 Ag of protein in a final volume of
100 Al of Tris–HCl pH 6.8 buffer, containing 1 mM sodium
deoxycholate, 100 mMNaCl, 40 mM LiCl, 1 mM EGTA and
the indicated concentrations of free calcium. Free calcium
concentrations were set using a Ca2 +-EGTA buffer system as
described by Herrero et al. [30].
2.6. Immunodetection of PLC b1 isoform
Fifty micrograms of protein were subjected to 7.5%
polyacrilamide gel electrophoresis in the presence of SDS.
Western blotting was performed as described earlier [18].
Nitrocellulose membranes were incubated with isoenzyme-
specific monoclonal anti-PLC antibody to PLC h1 (1:400).
After washing, blots were incubated with horseradish perox-
idase-coupled goat anti-mouse antibodies (1:3000). Antigen
was visualized using the ECL chemiluminescent detection kit
from Amersham and specific bands were quantified by
scanning densitometry.
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2.7. Protein determination
Protein concentration was measured by the method of
Lowry, using bovine serum albumin as standard.
2.8. Statistical and data analysis
Data statistical analysis was performed using the Stu-
dent’s t-test. Differences between mean values were consid-
ered statistically significant at P < 0.05. The binding data
were analyzed with the GraphPad Prism 3.02 program
(GraphPad Software, San Diego, CA, USA).
3. Results and discussion
Sprague–Dawley rats were daily treated with R-PIA, an
adenosine A1 receptor agonist. After 6 days of treatment,
animals were sacrificed, brain SPMs were isolated and the
status of different components of the mGlu receptor/PLC
pathway was studied.
First, binding assays were performed using L-[3H]gluta-
mate as radioligand in order to determine specific binding to
both total (ionotropic and metabotropic) and mGlu receptors
in rat brain SPM. When assays were performed with a single
concentration of radioligand (40 nM), an increase in total
and mGlu receptor binding was detected after R-PIA treat-
ment. This increase was of the same order (64–77%) with
all mGlu receptor agonists assayed, as it can be observed in
Table 1. To further study the effect of chronic adenosine A1
receptor activation on mGlu receptors, saturation curves
were performed with increasing L-[3H]glutamate concentra-
tions in control and treated SPM and in conditions in which
we detected either total or mGlu receptors. R-PIA treatment
caused a significant increase in Bmax value of total glutamate
receptors without a change in KD value, suggesting no
variation in receptor affinity (Fig. 1A and Table 2). Increase
in Bmax value was also observed when mGlu receptors
saturation curves were determined, as it is shown in Fig.
1B and Table 2. However, KD value increased significantly
after treatment suggesting a decrease in mGlu receptors
affinity. Therefore, higher specific binding of L-[3H]gluta-
mate shown in Table 1 can be explained by an increase in
total glutamate receptor number, which can be attributed to
the increase in metabotropic binding, this glutamate receptor
type being mainly affected by R-PIA treatment. These
results reveal that chronic R-PIA administration causes a
mGlu receptor up-regulation. Accordingly, persistent adeno-
Table 1
R-PIA treatment effect on glutamate specific binding to SPM from rat brain
Specific binding (pmol/mg protein)
Control R-PIA treated
Total glutamate binding 1.13F 0.17 1.95F 0.20*** (172%)
Metabotropic glutamate binding
L-Glutamate 0.63F 0.11 1.12F 0.06*** (177%)
Quisqualate 0.35F 0.03 0.59F 0.04*** (164%)
Trans-ACPD 0.38F 0.08 0.67F 0.03*** (172%)
Ibotenic acid 0.60F 0.08 1.01F 0.11*** (167%)
SPMs from control and R-PIA-treated rat brains were incubated with 40 nM
L-[3H]glutamate in binding conditions to all glutamate receptors subtypes
and specifically to mGlu receptors, as described in Materials and methods,
in the absence and in the presence of different mGlu receptor agonists at
100 AM to determine non-specific binding. Data are the meanF S.E. of at
least eight independent experiments performed in duplicate. ***P< 0.001
significantly different from control. Percentage respect to each control is
also indicated.
Fig. 1. R-PIA treatment effect on the saturation binding curve for both total
and metabotropic glutamate receptors. SPM (60–100 Ag protein) from
control and R-PIA-treated rat brain were incubated with L-[3H]glutamate in
a concentration range from 4 to 1000 nM (panel A, total glutamate receptor
binding), and from 4 to 1500 nM (panel B, metabotropic glutamate receptor
binding) as described in Materials and methods. Data points are the
meanF S.E. of at least four independent experiments performed in
duplicate, each using different membrane preparations. KD and Bmax values
from Scatchard analysis of saturation curves are shown in Table 2.
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sine A1 receptor activation with R-PIA increased h2-adre-
nergic receptors number in DDT1 MF-2 cells in a time- and
dose-dependent manner and decreased adenosine A1 recep-
tor number [12]. Similarly, we previously reported that
chronic in vivo R-PIA treatment, at the same doses and
administration method as that used in this work, causes a
decrease (ca. 50% of control) in total adenosine A1 receptor
number and functionality in rat brain SPM. This desensiti-
zation was associated with a significant increase in cAMP
level determined in SPM after treatment in basal, GTP- and
GTP plus forskolin-stimulated conditions (137.5%, 120%
and 132.2% of control, respectively) [31]. Basal as well as
forskolin- and isoproterenol-stimulated cAMP levels were
also significantly increased in adipocytes from R-PIA in-
fused rats [32], but significantly decreased in DDT1 MF-2
cells incubated with 3-isobutyl 1-methylxanthine (IBMX),
an adenosine receptor antagonist [33]. Moreover, a mGlu
receptor up-regulation following long-term h-AR activation
with isoproterenol has also been reported in rat C6 glioma
cells, where a Bmax increase of 67% was detected after 24 h
of isoproterenol treatment [18], when cAMP levels were
also higher in treated than in control cells although h-ARs
were strongly down-regulated [34]. Therefore, cross-talk
between adenosine A1 receptor and mGlu receptors detected
in rat brain after R-PIA treatment could be related to
increased cAMP levels.
One of the most widely described effector systems
coupled to mGlu receptors is the PLC h1 activity. Group I
mGlu receptors activation causes an increase in PLC activity
and inositol phosphate production through G-protein inter-
action, mainly Gq/11 type [26,35]. In order to study whether
R-PIA treatment also causes any modulation in the PLC
system, we determined this enzymatic activity in SPM from
control and treated rats, using [3H]PtdInsP2 as exogenous
substrate. First, we performed PLC assays using different
free calcium concentrations. As Fig. 2A shows, PLC activity
was calcium-modulated in a similar manner to that described
in plasma membranes from several tissues [30,36] and
intracellular organelles such as coated vesicles [37]. At
low concentrations of calcium, we detected a concentra-
tion-dependent increase in PLC activity with maximum
values observed at the micromolar range, while at higher
calcium levels, we detected a lower PLC stimulation. This
biphasic profile of concentration-dependent free calcium
modulation of PLC activity was very similar in R-PIA-
treated membranes. However, PLC activity was higher than
those detected in control conditions at all calcium concen-
Table 2
R-PIA treatment effect on kinetic parameters from saturation curves for
total and metabotropic glutamate receptors
Control R-PIA treated
Total glutamate binding
KD (nM) 315.5F 31.4 434.2F 112.6
Bmax (pmol/mg protein) 18.6F 1.4 33.6F 6.2**
Metabotropic glutamate binding
KD (nM) 663.3F 61.7 1074.7F 113.2***
Bmax (pmol/mg protein) 9.5F 0.2 24.6F 3.1***
KD and Bmax values were determined by Scatchard analysis of data from
saturation curves in Fig. 1. Data points are the meanF S.E. of at least four
independent experiments performed in duplicate, each using different
membrane preparations. **P < 0.005, ***P< 0.001 significantly different
from control values.
Fig. 2. R-PIA treatment effect on calcium and Gpp(NH)p modulation of
PLC activity from rat brain SPMs. Ten to fifteen micrograms of SPM from
control and treated rat brains were incubated with [3H]PtdInsP2 as
exogenous substrate in the absence (w/o Ca2 +) and in the presence of
increasing concentrations of calcium (panel A), and in the absence and in
the presence of different concentrations of Gpp(NH)p at 0.3 AM free
calcium (panel B). [3H]PtdInsP2 hydrolysis was determined as described in
Materials and methods. Basal PLC activities in the absence of Gpp(NH)p
were 5.29F 0.15 and 7.77F 1.30 pmol/mg proteinmin in control and
treated membranes, respectively. Data are the meanF S.E. of at least four
experiments performed in duplicate. *P< 0.05, **P < 0.005 significantly
different from control.
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trations assayed, and this difference was significant in the
micromolar range (Fig. 2A), suggesting a possible modu-
lation of PLC activity due to R-PIA treatment.
In order to determine the R-PIA treatment effect on G-
protein/PLC coupling, we measured PLC activity in the
presence of different concentrations of Gpp(NH)p, non-
hydrolyzable analogue of GTP, and in the presence of 0.3
AM free calcium. As it can be observed in Fig. 2B, in both
control and treated membranes, PLC activity is also modu-
lated by guanine nucleotides in a biphasic manner in the
concentration range assayed, being significant and maxi-
mum at 100 AM Gpp(NH)p. These results agree with
previous reports in rat cerebral cortex [38], membranes
prepared from rat salivary glands, GH3 cells, neutrophils,
hepatocytes and cerebral cortical tissue [39] and membranes
or coated vesicles from bovine brain [29]. However, an
increase in PLC activity was observed after R-PIA treat-
ment, again suggesting a positive modulation by adenosine
A1 agonist treatment. Basal and Gpp(NH)p-stimulated PLC
activity were increased similarly in R-PIA-treated versus
control membranes. These results suggest that this enhanced
activity could be due to an increase in the steady-state level
of the enzyme and, therefore, to a sensitization of the
enzymatic system. In order to verify this point, we per-
formed immunoblotting assays using specific PLC h1 iso-
form antibody. As Fig. 3 shows, a significant increase in the
quantity of h1 isoform was obtained after treatment, approx-
imately of the same order as that detected in PLC basal
activity determined using [3H]PtdInsP2 as substrate, con-
firming that observed variation in PLC activity was due, at
least partially, to an increase in the steady-state level of h1
isoform in membranes and suggesting a cross-talk mecha-
nism between cAMP and InsP3 second messenger path-
ways. Similar results have been described in C6 glioma cells
in which not only a sensitization of PLC activity but also a
significant increase in the PLC h1 isoform was detected
after prolonged stimulation of AC pathway through h-
adrenergic receptors [18]. Moreover, the increase in the
PLC h1 isoform in C6 cells was associated with an increase
in cAMP levels [34], which, as commented above, were also
increased in rat brain after in vivo R-PIA treatment [31].
Accordingly, continuous activation of AC system in CATH.a
cells results in the desensitization of the cyclic AMP pathway
and sensitization of the inositol phosphate signal, which
was also obtained after 16 h incubation of cells with 1 mM
Br-cAMP [40]. All these results suggest that cAMP
increase could mediate PLC sensitization detected in rat
brain after chronic in vivo adenosine A1 receptor activa-
tion.
Finally, in order to study the effect of R-PIA treatment on
mGlu receptor functionality, we determined the stimulatory
effect exhibited by trans-ACPD, selective mGlu receptor
agonist, on PLC activity. As it can be seen in Fig. 4, trans-
Fig. 3. Immunodetection of PLC h1 isoform in SPMs from rat brain.
Identical quantities (50 Ag) of SPM from control and R-PIA-treated rat
brain membranes were subjected to 7.5% SDS-PAGE, electrophoretically
transferred to nitrocellulose and probed with the isoform-specific mono-
clonal antibody against PLC h1 isoform, as described in Materials and
methods. The figure shows densitometric quantification of four independent
experiments performed with different membrane preparations. **P< 0.005
significantly different from control. Insert shows bands of a representative
experiment.
Fig. 4. R-PIA treatment effect on mGlu receptors/PLC activity coupling.
Ten to fifteen micrograms of SPM membranes from control and treated rats
were incubated with [3H]PtdInsP2 at 0.3 AM free calcium, in the presence of
100 AM Gpp(NH)p, 100 AM trans-ACPD or both, as described in Materials
and methods. Data are the meanF S.E. of at least four experiments
performed in duplicate. **P < 0.005, ***P < 0.001 significantly different
from control. All data were significantly different ( P < 0.001) from its
respective basal value in control and treated membranes.
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ACPD stimulated PLC activity (207% of basal activity) in
control membranes and this effect was higher in the pres-
ence of Gpp(NH)p (309% of basal activity), therefore
confirming the mGluR/PLC coupling through a G-protein.
In the same figure, it can be observed that R-PIA treatment
caused a significant increase in PLC activity detected in the
presence of trans-ACPD, Gpp(NH)p or both Gpp(NH)p and
trans-ACPD, the percentage of increment after R-PIA treat-
ment being similar in all cases assayed. This means that
mGluR/PLC pathway responsiveness to mGlu receptor ago-
nists is maintained after treatment, reaching higher values of
activity due to an increased level of PLC h1 protein and
mGlu receptor number. This increase in PLC system respon-
siveness has been reported in several cell cultures and
related to increased intracellular cAMP levels [9]. Thus,
chronic h-AR/AC stimulation with isoproterenol enhanced
both basal and mGluR mediated PLC activity in C6 glioma
cells [18], prolonged PACAP receptor/AC stimulation in
CATH.a cells caused an increase in both basal and PACAP
receptor mediated inositol phosphate production [40], and,
finally, long-term incubation with forskolin or dibutyryl
cAMP resulted in an increase in phosphoinositide hydrol-
ysis stimulated by bradykinin in parallel with an increase in
bradykinin receptors number in MC3T3-E1 osteoblast-like
cell line [41].
Taken together, results presented herein suggest that
chronic in vivo R-PIA treatment positively modulates
mGluR/PLC pathway, causing an up-regulation in both its
own receptor and effector system. The highlight of this work
is that an in vivo cross-talk mechanism between adenosine
A1 receptor and mGlu receptor operates in rat brain after
prolonged adenosine A1 receptor activation, which could be
mediated, at least partially, through increased cAMP levels.
However, other effects of adenosine A1 receptors (e.g.
control of calcium influx and glutamate release from nerve
terminals) could also be implicated. Because both adenosine
A1 and mGlu receptors are implicated in neurodegenerative
disorders, the existence of cross-modulation processes bet-
ween these receptor-mediated transduction pathways in vivo
could be important to be considered in future pharmaco-
logical treatments of those disorders.
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